GPT-Rosalind

OpenAI's frontier reasoning model built for biology, drug discovery, and translational medicine research, named after Rosalind Franklin.

OpenAI · Enterprise and vertical AI applications · model

Published in Feed

Overview

GPT-Rosalind is OpenAI's frontier reasoning model purpose-built to accelerate drug discovery, genomics analysis, protein reasoning, and translational medicine research, with improved tool use across chemistry, protein engineering, and genomics. It is available in ChatGPT, Codex, and the API for qualified customers through OpenAI's trusted access program, and OpenAI is working with life-sciences partners including Amgen, Moderna, the Allen Institute, and Thermo Fisher Scientific to apply it across research workflows. The model is named after Rosalind Franklin, whose research contributed to revealing the structure of DNA. OpenAI later updated the series to GPT-Rosalind-5.5, incrementally trained from GPT-5.5 with stronger medicinal chemistry and genomics performance, still gated to trusted research organizations. On October 30, 2026 OpenAI published GPT-Rosalind-6, which uses the same weights as GPT-6 Astra with no added training data or post-training and fewer refusals on dual-use biology queries, available only through trusted access. OpenAI's system card reports a biorisk-knowledge refusal rate of 9.4% (1.8% for GPT-Rosalind-5.5, 29.2% for GPT-6 Astra) and gains over GPT-Rosalind-5.5 on MedChemBench v7 (49.6% vs 28.9%), GeneBench Pro v13 (37.7% vs 16.7%) and LifeSciBench Gold (61.3% vs 44.0%) at the highest reasoning budget; it is rated High in Biological and Chemical and Critical in Cybersecurity under the Preparedness Framework.

This is a sourced directory entry. Features and capabilities are reported in the linked sources; this entry does not document independent Aymorphic testing.

Key features

  • Frontier reasoning tuned for biology, drug discovery, and translational medicine
  • Improved tool use and understanding across chemistry, protein engineering, and genomics
  • Available through OpenAI's trusted access program, not general self-serve access
  • Launch partners include Amgen, Moderna, the Allen Institute, and Thermo Fisher Scientific
  • GPT-Rosalind-6 (Oct 30, 2026): GPT-6 Astra weights with relaxed dual-use biology refusals, trusted access only
  • GPT-Rosalind-6 vs -5.5: MedChemBench v7 49.6% vs 28.9%, GeneBench Pro v13 37.7% vs 16.7% (OpenAI-reported)

Use cases

  • Target discovery and hypothesis generation in drug development
  • Genomics and protein-engineering analysis workflows
  • Translational medicine research at pharma and biotech organizations

Pricing

Gated trusted-access program for qualified life-sciences customers; pricing not publicly listed.

Pricing reflects the source record and may change. Confirm current terms with the provider.

Dates and sources

Released
Not listed
Record updated
2 Nov 2026
Record last checked
2 Nov 2026

Explore the Feed

Other entries filed under enterprise and vertical ai applications; inclusion does not imply equivalent features.

  • Expert Intelligence

    O'Reilly's enterprise toolkit that grounds AI coding and work assistants in cited, dated practitioner knowledge via an MCP-compatible connector.

  • AI Employees

    Ema's platform of autonomous 'AI Employee' agents automating HR, IT, and finance workflows, which just raised a $77M Series B quadrupling its valuation.

  • Claude for Government

    Anthropic's FedRAMP High authorized environment bringing Claude's coding and agentic capabilities to U.S. federal and state agencies.

Browse the Feed